Polygenic Score (PGS) ID: PGS000058

Predicted Trait
Reported Trait Coronary artery disease
Mapped Trait(s) coronary artery disease (EFO_0000378)
Released in PGS: Dec. 18, 2019

Score Details

Score Construction
PGS Name CAD_GRS_204
Variants
Original Genome Build hg19
Number of Variants 204
Development Method
Name Genome-wide significant SNPs
Parameters Variants with a genome-wide significant associations with CAD in GWAS and exome-wide association studies published as of December 2017
PGS Source
PGS Catalog Publication (PGP) ID PGP000043
Citation (link to publication) Morieri ML et al. Diabetes Care (2018)

Contributing Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry
EuropePMC: 26934567
[
  • 42,335 cases
  • , 78,240 controls
]
European
GWAS Catalog: GCST005194
EuropePMC: 29212778
296,525 individuals NR
GWAS Catalog: GCST003116
EuropePMC: 26343387
11,323 individuals East Asian
GWAS Catalog: GCST003116
EuropePMC: 26343387
25,557 individuals South Asian
GWAS Catalog: GCST003116
EuropePMC: 26343387
2,268 individuals Greater Middle Eastern (Middle Eastern, North African or Persian)
GWAS Catalog: GCST003116
EuropePMC: 26343387
4,095 individuals Hispanic or Latin American
GWAS Catalog: GCST003116
EuropePMC: 26343387
141,217 individuals European
GWAS Catalog: GCST003116
EuropePMC: 26343387
3,139 individuals African American or Afro-Caribbean
GWAS Catalog: GCST004787
EuropePMC: 28714975
63,731 individuals European, NR
GWAS Catalog: GCST007990
EuropePMC: 28714974
120,286 individuals European
GWAS Catalog: GCST000999
EuropePMC: 21378988
14,790 individuals South Asian
(India, Pakistan)
GWAS Catalog: GCST000999
EuropePMC: 21378988
15,682 individuals European
EuropePMC: 28209224
[
  • 42,335 cases
  • , 78,240 controls
]
European
EuropePMC: 28584231
[
  • 10,898 cases
  • , 76,535 controls
]
,
50.81 % Male samples
European
EuropePMC: 28530674
[
  • 88,192 cases
  • , 162,544 controls
]
Other
EuropePMC: 23202125
[
  • 63,746 cases
  • , 130,681 controls
]
Other

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID)
PGS Sample Set ID
(PSS ID)
Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000148 PSS000093 PGP000043
Morieri ML et al. (2018)
Reported Trait: Major coronary events (MCE) events among Type 2 Diabetes patients HR: 1.35[1.16, 1.58] age, sex, ORIGIN study covariates (randomized treament assignement, PCs of genetic ancestry)
PPM000147 PSS000092 PGP000043
Morieri ML et al. (2018)
Reported Trait: Major coronary events (MCE) events among Type 2 Diabetes patients HR: 1.27[1.18, 1.37] age, sex, ACCORD study covariates (randomized treament assignement, clinical network, genotyping platform, PCs of genetic ancestry)

Evaluated Samples

PGS Sample Set ID
(PSS ID)
Detailed Phenotype Description Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000092 Incident Major coronary events (MCE) are defined as: fatal or nonfatal coronary artery disease (CAD) events, nonfatal myocardial infarction, or unstable angina Median = 4.7 years
[
  • 675 cases
  • , 4,685 controls
]
,
64.8 % Male samples
Mean = 62.8 years European Self reported white ACCORD Type 2 Diabetes patients
PSS000093 Incident Major coronary events (MCE) are defined as: fatal or nonfatal coronary artery disease (CAD) events, nonfatal myocardial infarction, or unstable angina Median = 6.2 years
[
  • 163 cases
  • , 1,768 controls
]
European Self reported white ORIGIN Participants are from the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial and were enrolled based on having some combination of impaired fasting glucose, impaired glucose tolerance or type 2 diabetes, and high cardiovascular risk